Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer

被引:50
作者
Shi, Zhi [1 ,2 ]
Tiwari, Amit K. [1 ]
Patel, Atish S. [1 ]
Fu, Li-Wu [2 ]
Chen, Zhe-Sheng [1 ]
机构
[1] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Allied Hlth Profess, Queens, NY USA
[2] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
基金
美国国家卫生研究院;
关键词
BREAST-TUMOR CELLS; PHASE-I; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; VINCRISTINE RESISTANCE; CYCLIC-NUCLEOTIDES; CYCLOSPORINE-A; COMBINATION; VINBLASTINE; DOXORUBICIN;
D O I
10.1158/0008-5472.CAN-11-0375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The phenomenon of multidrug resistance (MDR) has decreased the hope for successful cancer chemotherapy. The ATP-binding cassette (ABC) transporter superfamily is the largest transmembrane family. The overexpression of ABC transporters is a major determinant of MDR in cancer cells both in vitro and in vivo. Unfortunately, until recently, most of the strategies used to surmount ABC-transporter-mediated MDR have had limited success. An ideal modulator of MDR would be one that has a low liability to induce toxicity and alter the pharmacokinetic profile of antineoplastic drugs. Sildenafil, an inhibitor of cGMP-specific phosphodiesterase type 5, was found to significantly reverse ABC-transporter-mediated MDR. Our results indicate that sildenafil has differential inhibitory effects on ABC transporters: It significantly decreases the efflux activity of ABCB1 and ABCG2, but has no significant effects on ABCC1. Emerging evidence indicates that sildenafil and other phosphodiesterase type 5 inhibitors may enhance the sensitivity of certain types of cancer to standard chemotherapeutic drugs. Cancer Res; 71(11); 3735-8. (C)2011 AACR.
引用
收藏
页码:3735 / 3738
页数:4
相关论文
共 31 条
[1]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[2]   PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE [J].
BARTLETT, NL ;
LUM, BL ;
FISHER, GA ;
BROPHY, NA ;
EHSAN, MN ;
HALSEY, J ;
SIKIC, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :835-842
[3]  
Bates S, 2001, CANCER-AM CANCER SOC, V92, P1577, DOI 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO
[4]  
2-H
[5]   Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use [J].
Bender, Andrew T. ;
Beavo, Joseph A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :488-520
[6]  
BENSON AB, 1985, CANCER TREAT REP, V69, P795
[7]   PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model [J].
Black, Keith L. ;
Yin, Dali ;
Ong, John M. ;
Hu, Jinwei ;
Konda, Bindu M. ;
Wang, Xiao ;
Ko, MinHee K. ;
Bayan, Jennifer-Ann ;
Sacapano, Manuel R. ;
Espinoza, Andreas ;
Irvin, Dwain K. ;
Shu, Yan .
BRAIN RESEARCH, 2008, 1230 :290-302
[8]   Transport of cyclic nucleotides and estradiol 17-β-D-glueuronide by multidrug resistance protein 4 -: Resistance to 6-mercaptopurine and 6-thioguanine [J].
Chen, ZS ;
Lee, K ;
Kruh, GD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33747-33754
[9]   Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction [J].
Das, Anindita ;
Durrant, David ;
Mitchell, Clint ;
Mayton, Eric ;
Hoke, Nicholas N. ;
Salloum, Fadi N. ;
Park, Margaret A. ;
Qureshi, Ian ;
Lee, Ray ;
Dent, Paul ;
Kukreja, Rakesh C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (42) :18202-18207
[10]   Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells [J].
Di, Xu ;
Gennings, Chris ;
Bear, Harry D. ;
Graham, Laura J. ;
Sheth, Christopher M. ;
White, Kimber L., Jr. ;
Gewirtz, David A. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) :349-360